Anti-inflammatory Effects of S. cumini Seed Extract on Gelatinase-B (MMP-9) Regulation against Hyperglycemic Cardiomyocyte Stress

Neha Atale 1, Chandra Bhushan Mishra 2, Shrey Kohli 3, Raj Kumar Mongre 2, Amresh Prakash 4, Sweta Kumari 5, Umesh C. S. Yadav 6, Raok Jeon 2, and Vibha Rani 1

1Department of Biotechnology, Jaypee Institute of Information Technology, A-10, Sector-62, Noida, 201307 Uttar Pradesh, India
2College of Pharmacy, Sookmyung Women’s University, Hyochangwon-gil 52, Yongsan-13 Gu, Seoul 140-742, Republic of Korea
3Institute for Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig (Medical Faculty), Leibigstr. 27, 04103 Leipzig, Germany
4Amity Institute of Integrative Sciences and Health, Amity University, Gurgaon 122413, Haryana, India
5Division of Biochemistry, Indian Agricultural Research Institute (IARI), Pusa Campus, 110012, New Delhi, India
6School of Life Sciences, Central University of Gujarat, Sector-30, Gandhinagar, 382030 Gujarat, India

Correspondence should be addressed to Raok Jeon; rjeon@sookmyung.ac.kr and Vibha Rani; vibha.rani@jiit.ac.in

Received 5 September 2020; Revised 4 December 2020; Accepted 16 February 2021; Published 4 March 2021

1. Introduction

Syzygium cumini, a seasonal perishable berry, commonly known as malabar plum, belongs to the family Myrtaceae. The plant is native to Asia and Oceanic regions, mainly India, China, and New Zealand. It is also grown in East Africa, South America, and tropical parts of the USA [1, 2]. The purple fruits of jamun are used for the processing of chips, vinegar, jams, smoothies, and squashes and hold a significant position in the functional food industry. Besides the fruits, other parts of the plant also have been found useful in treating chronic diseases including diabetes-related complications [3, 4]. The plant of S. cumini, especially its fruit, is considered a functional food, as it consists of plenty of polyphenols such as gallic acid, quercetin, β-sitosterol, eicosane, diphenic acid, ellagic acid, isoquercetin, and myricetin, which may facilitate healthy benefits against diabetes-induced detrimental changes and also reduce the risk of neurological and cardiovascular diseases (CVDs) [5]. These molecules are known for their anti-inflammatory, antihyperlipidemic, antioxidative, free radical scavenging, and antidiabetic potential [6]. Further studies have shown that S. cumini seed extracts function
as a chemopreventive agent against DNA damages and also have antimutagenic as well as antigenotoxic effects [7].

Cardiac stress has become a leading cause of morbidity and mortality among people with type 2 diabetes. Diabetic individuals have two to four times greater risks of cardiac arrest than nondiabetic people [8, 9]. The alarming rate of diabetes incidences and its impact on the heart make diabetic cardiomyopathy a challenging health condition worldwide. However, the effect of S. cumini seed polyphenolic constituents on diabetes-induced cardiac stress is not known. Thus, it is important to study the effect of MSE against diabetes-induced cardiac stress along with its mechanism of action which may open a new way for the management of cardiomyopathy.

Hyperglycemia is known to cause cardiac stress, which eventually leads to cardiomyopathy through increased activity of matrix metalloproteinases (MMPs) and extracellular matrix (ECM) remodeling [10]. MMPs are a family of secreted and membrane-bound zinc and calcium-dependent endopeptidases, which include collagenases, gelatinases, stromelysins, matrilysins, and a few peptidases [11–13]. The variation in the expression of MMPs and endogenous tissue inhibitors of matrix metalloproteinases (TIMPs), especially TIMP-1 and TIMP-2, may lead to the pathophysiology of various diseases including cardiovascular diseases, cancer, diabetes, and neurodegenerative disorders [14]. TIMPs act as inhibitors for active MMPs by binding to the Zn²⁺ in its catalytic domain [14, 15]. Their production is regulated by a variety of mediators including cytokines, chemokines, hormones, and growth factors [16]. The inflammatory cytokines and growth factors released at tissue damage sites lead to the enhancement of the expression of MMP-9 and among which TNF-α is found to be a potent stimulator of MMP-9 transcription and atherosclerosis [17].

The central role of MMPs in ECM remodeling, therefore, makes them a potential drug target in diabetic cardiomyopathy [18, 19]. One of the critical MMPs known to be activated in diabetes is MMP-9, the largest and the most complex member which otherwise remains latent in healthy hearts. During diabetic cardiomyopathies, gelatinase-B also called MMP-9 activated via Ras/Raf/MEK/ERK signaling cascade causes extensive degradation of ECM and decreases matrix turnover, which is associated with several cardiac abnormalities and heart failure [20]. Although there has been a big thrust towards the development of synthetic MMP inhibitors, their safe implementation and testing in successful clinical trials is still a challenge [21].

Overwhelming evidence from epidemiological, in vivo, in vitro, and clinical studies indicates that plant-based functional foods not only provide basic nutrition but also have the potential to suppress diseases and ensure good health and longevity. Therefore, efforts to identify new plant-based MMP inhibitors, with less toxicity and more specificity, are required [22]. To date, specific studies revealed the inhibition of MMPs by several natural products such as dietary gallic acid, epigallocatechins, anthocyanins, curcumin, and caffèic acid in various pathological conditions [23, 24].

Syzygium cumini has been extensively studied for its nutrient composition and found to be enriched with polyphenols and could serve as a source of a potential MMP inhibitor that can be effective in HG-induced cardiac stress [6, 25]. Our previous studies found that S. cumini MSE significantly suppressed the HG-induced stress in H9C2 cardiomyocytes by reducing mitochondrial membrane potential, reactive oxygen species (ROS) overproduction, and collagen levels, suggesting its potential as a functional food and supplementary diet to diabetic patients for suppression of cardiac stress [26]. In the present study, we have examined the role of MSE as well as the purified component of seed extract on MMP-9 expression and activity in HG-stressed cardiomyocytes. Our current study also proposes S. cumini to be a potent MMP inhibitor and a therapeutic agent in diabetes-induced cardiac complications.

2. Materials and Methods

A schematic representation of the methodology used in the present study is illustrated in Fig. S1.

2.1. Chemicals. All chemicals were purchased from Sigma Aldrich (St. Louis, MO, USA). All the antibodies were purchased from Santa Cruz Biotechnology Inc. (Dallas, TX, USA).

2.2. Seed Collection. S. cumini seeds were procured from a local vendor in the month of July-August and were authenticated by Dr. Anshu Rani, an eminent botanist, Department of Botany, Govt. P.G. College, Abu Road, Rajasthan, India. Further, the seeds were washed, ground, and dried.

2.3. Preparation of Methanol Extract of S. cumini Seeds. The methanol extract of S. cumini seeds (MSE) was prepared by using the Soxhlet solvent extraction method. Seed powder (20 g) was mixed with 200 ml methanol. The temperature was set at its boiling point (64.7 °C), and 12-14 cycles were run for complete extraction. After solvent evaporation in a rotary evaporator, the dried powder was reconstituted at the concentration of 1 mg/ml in molecular-grade water.

2.4. Cell Culture. The rat heart-derived H9C2 cardiomyoblast cells were obtained from the National Centre for Cell Science (NCCS), Pune, India (originally from ATCC, USA). H9C2 cells were cultured with Dulbecco’s modified Eagle’s medium (DMEM) supplemented with penicillin (100 unit/ml), streptomycin (100 µg/ml), glucose (5.5 mM), L-glutamine (2 mmol/l), sodium bicarbonate (3.7 g/l), 10% fetal bovine serum (FBS), insulin (50 µg/ml), transferrin (27.5 µg/ml), selenium (0.025 mg/ml), and amphotericin B (5 µg/ml) in a humidified CO₂ incubator (New Brunswick Scientific, NJ, USA) with 5% CO₂ at 37°C [27].

2.5. Treatment of Cells with Glucose, S. cumini MSE, and Gallic Acid (GAL). H9C2 cells were induced with optimized doses of glucose and S. cumini MSE as standardized in our previous studies [28]. The gallic acid was used as a purified equivalent in all the experiments. Our study included six groups: (a) control (untreated) cells, (b) cells induced with...
4.5 mg/ml glucose (HG), (c) high-glucose-induced cells treated with S. cumini MSE (9 μg/ml) (HG+MSE), (d) MSE-treated cells (MSE), (e) high-glucose-induced cells treated with gallic acid (3.4 μg/ml) (HG+GAL), and (f) gallic acid-treated cells (GAL).

2.6. Cell Viability Assay. Cell viability was determined by a 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay (Ferrari, Fornasiero & Isetta, 1990). Approximately 8×10^3 H9C2 cells were seeded in 96-well plates. The H9C2 cells were treated as described above and incubated for 48 h at 37°C in a humidified incubator containing 5% CO₂. After completion of incubation, 10 μl MTT (5 mg/ml) was added, and cells were further incubated for 3 h. The culture supernatant was then discarded, and formazan crystals were dissolved in 100 μl DMSO. Absorbance was measured through an ELISA plate reader (ThermoFisher Scientific Inc., Waltham, MA, USA) at 570 nm. Cell viability was defined in relation to control cells as the ratio of absorbance of the treated sample to absorbance of the control sample.

2.7. Haematoxylin-Eosin (H&E) Staining. The H&E staining was performed for the determination of morphology of cells. H9C2 cells were seeded in six-well plates as per the experimental sets described earlier and incubated for 48 h. Subsequently, cells were washed with cold phosphate-buffered saline (PBS) and fixed with 100% chilled (-20°C) methanol. Haematoxylin (0.5% alcoholic solution) was added and incubated for 30 min at 25°C. After washing twice with PBS at room temperature, cells were counterstained with 5% eosin, washed, and mounted. The cells were observed under a light microscope, and images were captured at 40x magnification. The stained cells were eluted with 0.1 N NaOH, and the absorbance of samples was measured at 560 nm.

2.8. Extraction of Total Cell Protein. After completion of 48 h of incubation, cells were harvested and washed with cold PBS. The cell pellet was lysed in precooled 1x RIPA buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 500 mM Na₂EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, and protease inhibitor cocktail (104 mM AEBSF, 80 μM aprotinin, 4 mM bestatin, 1.4 mM E-64, 2 mM leupeptin, and 1.5 mM pepstatin A) on ice for 1 h. The cell lysate was centrifuged at 13000 × g for 15 min at 4°C in a refrigerated centrifuge. The concentration of total cell proteins in supernatant was estimated by a Bradford assay.

2.9. Gel Diffusion Assay. A solution containing 1.5% agarose, digestion buffer (50 mM Tris-Cl (pH 7.4), 150 mM NaCl, 5 mM CaCl₂, and 0.02% Brij-45), and 1 mg/ml gelatin was poured on a gel plate and allowed to solidify. An equal amount of protein (30 μg/ml) from various experimental sets were loaded into wells punched in the solidified agarose gel and incubated overnight at 37°C. Zones of gelatin digestion were detected by staining the agarose gel in a solution containing 0.25% Coomassie Brilliant Blue R-250. The enzymatic activity was estimated as a function of the diameter of the digested zone compared to standard trypsin.

2.10. Zymographic Analysis of MMP-9 Production. The equal amount of protein (30 μg/ml) from different experimental sets was mixed with 2x sample buffer (0.005% Bromophenol Blue, 20% glycerol, 4% SDS, 100 mM Tris-Cl (pH 6.8)) in equal proportion and subjected to electrophoresis in 10% polyacrylamide gel containing gelatin (1 mg/ml). After washing with 2.5% Triton X-100, the gels were incubated in digestion buffer, stained with 0.25% Coomassie Brilliant Blue R-250, and further destained to visualize gelatinolytic activities in zymogram which was observed as transparent bands against the background of Coomassie Blue-stained gelatin containing gel. The quantitation was done using NIH ImageJ software.

2.11. Cell In Situ Zymography. H9C2 cells were cultured on coverslips and were fixed with chilled (-20°C) methanol and implanted in the uniformly spread mixture of 0.5% agarose containing 0.1% fluorescein-conjugated gelatin on the glass slides. The cells were incubated at 37°C for 1 h in developing buffer (50 mM Tris-Cl (pH 7.4), 150 mM NaCl, 5 mM CaCl₂, 0.02% Brij-45) and visualized under a fluorescent microscope (Olympus Corporation, KYO, Japan). Images were captured at 40x magnification.

2.12. Immunocytochemistry. H9C2 cells were grown on coverslips under different experimental conditions and fixed with methanol. After washing the cells with PBS, blocking was done for 1 h at room temperature (25°C) using 3% BSA prepared in PBS followed by incubation with primary antibodies (against MMP-9, NF-κB, GAPDH, and Lamin A/C) for 1 h at 37°C. Subsequently, cells were stained with FITC-conjugated secondary anti-goat antibody under similar conditions. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) as described previously [29] and observed under a fluorescent microscope (Olympus Corporation, KYO, Japan). Images were captured using a Progress capture camera fitted to the microscope. Overlay images were obtained by NIH ImageJ software.

2.13. RT-PCR. After completion of incubation, total RNA was extracted using a TRizol reagent (Invitrogen Carlsbad, CA, USA) as per the manufacturer’s manual. Reverse transcription of all sets with 0.1 μg total RNA was performed using a RevertAid HMinus First Strand cDNA Synthesis Kit (ThermoFisher Scientific Inc., Waltham, MA, USA) as per instructions provided. The cDNA samples were diluted to 20 ng/μl. The thermal cycling conditions were composed of an initial denaturation step at 95°C for 5 min followed by 30 cycles at 95°C for 30 s each, the respective annealing temperature for 30 s and 72°C for 30 s, and a final extension of 10 min at 72°C. Amplified products were resolved on 2% agarose gel and visualized by ethidium bromide staining using GelDoc (BioRad Laboratories, CA, USA). The primer sequences for specific genes and their respective annealing temperatures were as follows: MMP-9: 5′-CACCCTCTACCCCTACCCGCG-3′ (F), 5′-TGCCGATTGGCCCGAGTTA-3′ (R), 66°C; TNF-α: 5′-AGAAATCGACGTCTCTCC-3′ (F), 5′-ACTCAGGAAAGTGACCTGCG-3′ (R), 56°C; IL-6: 5′-CCTACCAACACTTCCAATGCTC-3′ (F), 5′-TTGGAT...
GGTCTTGGTCCCTAGCC-3′ (R), 58.5°C; and β-Actin: 5′-CATCGTACTCCTGCTTGCTG-3′ (F), 5′-CCTCTATGC
CACACAGTGCC-3′ (R), 57.5°C. To further validate the semiquantitative results, qRT-PCR was carried out using SYBR Green PCR master mix of the PikoReal™ Real-Time PCR System (ThermoFisher Scientific Inc. Waltham, MA, USA). Upon completion, fold changes in gene expression were calculated by a delta delta Ct (ΔΔCt) method. The fold change in gene expression was normalized to an internal β-actin control gene.

2.14. HPLC Analysis. Methanol extract of S. cumini seeds and 10 standards, namely, ellagic acid, gallic acid, p-coumaric acid, quercetin, protocatechuic acid, sinapic acid, caffeic acid, kaempferol, ferulic acid, and p-hydroxybenzoic acid (Sigma-Aldrich, St. Louis, MO, USA), was subjected to HPLC analysis by using Shimadzu LC instrument equipped with Hypersil C-18 column and PDA detector (Shimadzu Corporation, Kyoto, Japan). Mobile phase containing methanol/acetonitrile (98/2 v/v) was used to perform HPLC analysis [30–32]. The flow rate was set at 0.5 ml/min, and the absorbance used for this study was 254 nm. 100 μl MSE, taken from 150 ml stock solution obtained from 10 g S. cumini seed powder, was diluted with 900 μl HPLC-grade methanol and filtered through 0.2 μm filter (Millipore, MA, USA). From the diluted stock, 20 μl was used for HPLC analysis. For HPLC analysis of the standards, 1 mg/ml stocks were prepared in methanol, and 20 μl of each standard was subjected to HPLC analysis. The concentration of each component of the extract was calculated by using the area of different standards individually. The results are represented as the mean ± SD, and each experiment is performed in triplicate.

2.15. Molecular Docking. AutoDock Vina was used for docking studies [33]. The X-ray crystallographic structure of MMP-9 (Pdb id 4H82) was selected from the protein structure database (protein data bank RCSB PDB). The ligand molecular structure of ellagic acid, gallic acid, p-coumaric acid, quercetin, protocatechuic acid, sinapic acid, caffeic acid, kaempferol, ferulic acid, and p-hydroxybenzoic acid was designed and 3D optimized using ACD ChemSketch 12.0. A grid box of 20 × 20 × 20 points was generated around the active site coordinates of MMP-9 protein. The binding free energies of the ligand-protein interactions were also calculated using the best-predicted conformations in the bounded state and compared with binding free energies of MMP-9-doxycycline interactions [34–39].

2.16. Statistical Analysis. The data are expressed as means ± SD. Statistical analysis was performed using SPSS 16 software. Statistical comparisons were made with one-way ANOVA with Tukey’s test. All the results were considered significant with a p value ≤ 0.05. Each experiment was conducted in triplicates and repeated thrice.

3. Results

3.1. S. cumini Prevents Glucose-Induced Cardiac Stress. To evaluate the protective effect of S. cumini on glucose-induced cardiac stress, H9C2 cardiomyocytes were treated with high glucose (4.5 mg/ml, 25 mM) alone or high glucose concomitantly with S. cumini MSE. Gallic acid which is a known cardioprotective agent under diabetes conditions was used as a positive control. Morphological assessment by H&E staining showed that although high-glucose treatment results in about 1.5-fold increase in cell size, treatment with MSE prevented the increase in cell size as effective as gallic acid treatment (Figure 1). Furthermore, neither MSE nor gallic acid resulted in any cytotoxic or morphological alterations indicating that either treatment does not exert any harmful effects on cardiac cells themselves but are protective under glucose-induced stress conditions.

3.2. S. cumini Prevents Glucose-Induced Gelatinase Activity in H9C2 Cardiomyocytes. Cardiac remodeling involving molecular changes that manifest as increased cell size under disease conditions is known to be regulated by ECM remodeling matrix metalloproteinases (MMPs 2& 9), popularly known as gelatinases. We, therefore, studied whether the protective effect of S. cumini MSE is regulated by these gelatinases. We first studied the ability of lysates from H9C2 cardiomyocytes to digest gelatin as a substrate in a gel-diffusion assay evaluated by the area of digestion zone (Figure 2(a)). We found that treatment with high glucose resulted in an enhanced gelatinase activity (equivalent to 102 U trypsin) compared to untreated controls (equivalent to 45 U trypsin) which was prevented upon concomitant treatment with S. cumini MSE (equivalent to 55 U trypsin). Likewise, gallic acid was also protective against glucose-induced gelatinase activity (equivalent to 58 U trypsin), and gallic acid or MSE treatment alone did not result in any significant change in gelatinase activity (equivalent to 49 U and 50 U trypsin, respectively) compared to controls. We then performed gelatin zymography using protein lysates under similar experimental conditions to evaluate the MMP activity (Figure 2(b)). We found similar results as obtained above where high-glucose treatment resulted in enhanced MMP activity which was prevented by concomitant treatment with S. cumini MSE or gallic acid. In order to further confirm the protective effects of S. cumini MSE on glucose-induced MMP activity, we then performed cell in situ zymography to map the in-position cell matrix metalloproteinase activity using FITC-conjugated gelatin (Figure 2(c)). We found that cells treated with high glucose alone were much more efficient in digesting FITC-gelatin resulting in enhanced fluorescence intensity compared to controls indicating an increased MMP activity. Intriguingly, treatment with either S. cumini MSE or gallic acid under high-glucose conditions resulted in only a weak fluorescence signal indicating a reduced MMP activity, and either treatment was protective. Akin to the results obtained above, MSE or gallic acid treatment alone did not have any significant effect on MMP activity compared to the control. Overall, these results suggested that S. cumini MSE exerts an inhibitory effect on glucose-induced MMP activity in cardiomyocytes which was as competent as gallic acid, a previously known cardioprotective agent as well as a phytocomponent of S. cumini.
3.3. *S. cumini* Prevents Glucose-Induced Gelatinase-B Expression in H9C2 Cardiomyocytes. Although a generalized MMP activation in cardiomyopathies has been witnessed, a specific induction of gelatinase-B has been reported in diabetic cardiomyopathy. We therefore selected gelatinase-B as a potential therapeutic target for further assessment. Semi-quantitative RT-PCR as well as qRT-PCR analysis showed that high-glucose treatment results in an elevated mRNA expression of gelatinase-B compared to the control (Figure 3(a)). Furthermore, treatment with *S. cumini* MSE under high-glucose conditions significantly prevented the increase in gelatinase-B mRNA expression. Intriguingly, this inhibitory effect of *S. cumini* MSE on gelatinase-B mRNA expression was stronger as compared to that of gallic acid. Immunohistochemistry analysis of H9C2 cardiomyocytes treated under similar conditions showed that *S. cumini* MSE treatment under high-glucose conditions prevented the increase in gelatinase-B protein expression (Figure 3(b)). Taken together, these results suggested that *S. cumini* MSE suppresses the gelatinase-B protein as well as mRNA expression in high-glucose-treated H9C2 cardiomyocytes.

3.4. *S. cumini* Prevents Glucose-Induced NF-κB Nuclear Translocation and Cardiac Inflammation. MMP expression has been shown to be regulated by redox-sensitive transcription factor NF-κB. Importantly, we observed that *S. cumini* treatment altered not only gelatinase-B protein expression but also its mRNA expression. This indicated that the protective effect of *S. cumini* on gelatinase-B could be regulated at the transcriptional level. NF-κB transcriptional activity is dependent upon its translocation to the nucleus. Therefore, we studied the nuclear localization of NF-κB protein using antibodies of p65 (RelA) subunit of NF-κB protein by immunoblotting (Figure 4). We observed that upon high-glucose treatment, NF-κB translocated more from the cytoplasm to the nucleus compared to controls indicating its activation. However, treatment of *S. cumini* along with high glucose shows a reduced localization of NF-κB in the nucleus compared to controls and was similar to that observed in controls. Similarly, gallic acid treatment under high glucose conditions also showed its predominant localization in the cytoplasm indicating its reduced activation. These results suggested that *S. cumini* MSE treatment inhibits NF-κB nuclear translocation further controlling their gelatinase-B expression.

An increase in NF-κB nuclear translocation would enhance not only gelatinase-B expression but other proinflammatory cytokines such as TNF-α and IL-6. We, therefore, evaluated the mRNA expression of these cytokines (Figures 5(a) and 5(b)). We found that high-glucose treatment exacerbated the expression of TNF-α and IL-6, respectively, and *S. cumini* MSE treatment was able to prevent it. Gallic acid treatment also decreased the expression of TNF-α and IL-6 similar to *S. cumini* MSE. On the one hand, these results suggested that *S. cumini* MSE is able to prevent glucose-induced cardiac inflammation; on the other hand,
it corroborated a reduced activity of NF-κB. However, additional evidence would be required to assert a direct correlation between NF-κB activity and cytokine expression.

3.5. *S. cumini* Phenolic Compounds Block Gelatinase-B Substrate Binding. We have previously shown potent antioxidative potential of *S. cumini* extracts indicating that *S. cumini* is rich in phenolic compounds. To evaluate this, we performed reverse-phase HPLC of *S. cumini* MSE which showed that indeed *S. cumini* MSE is enriched with a concoction of polyphenols, viz., corilagin, doxycycline, ellagic acid, ferulic acid, epigallocatechin gallate, gallic acid, kaempferol, quercetin, and sinapic acid (Figure 6). The structures, retention time, and quantity of these polyphenols are shown in Table S1. The presence of these polyphenols was validated using standard polyphenols in HPLC (Fig. S2). The protective effects of these polyphenols have been shown to be implicated in several diseases.

Our results showed that *S. cumini* MSE has a protective function under high-glucose conditions by inhibiting NF-κB translocation and gelatinase-B expression as well as activity, but whether it had a direct influence on gelatinase-B activity remains unresolved. We therefore evaluated if *S. cumini* polyphenols have a tendency to bind to MMP-9. *In silico* molecular docking studies showed that these polyphenols have a binding tendency to MMP-9 with variable interactions.
binding energies (Figures 7(a)–7(c)). Of these, quercetin had the maximum binding energy followed by kaempferol, ferulic acid, and caffeic acid. Interestingly, gallic acid showed the least binding energy explaining a better efficacy of S. cumini MSE than gallic acid in some of the results obtained above. Intriguingly, all the polyphenols were docked on the Zn$^{2+}$ metal-binding site (consensus sequence HEBGxHxLGLxHS), on three histidine residues (His226, His230, and His236) which belong to the substrate-binding site of MMP-9. These results show that despite the fact that S. cumini MSE regulates gelatinase-B expression via NF-κB activity, the polyphenols within the MSE are capable of binding directly to gelatinase-B and could therefore have a direct effect on gelatinase-B activity.

**4. Discussion**

Diabetes and its long-term complications are a serious threat worldwide despite the availability of significant therapeutic options. Epidemiological and pathophysiological studies indicate that diabetes mellitus (DM) patients have increased risks of cardiovascular diseases. Even a slight increase in the hemoglobin A1c (HbA1c) level may lead to 20–30% upsurge in CVDs [40]. ECM dysfunction and alteration in MMP activity lead to the degradation of various structural proteins and several CVDs. MMP inhibitors have been shown to be effective in mediating efficient cardioprotection. However, due to the poor bioavailability, high toxicity, and failure of synthetic MMP inhibitors in clinical trials, attention has shifted to plant-derived MMP inhibitors [41].

The polyphenolic content-enriched functional food could have shown a promising approach towards the treatment of such diseases. Such natural product-derived drugs would have limited toxicity and side effects with better therapeutic indices [42]. The role of S. cumini seeds on HG-induced cardiac stress is not known so far; therefore, in the present study, methanol extract of S. cumini seeds was used to examine its effect on HG-induced cardiomyocytes. The effect was also examined with a purified form of a known constituent of S. cumini seed extract, gallic acid, a well-known cardioprotectant in diabetes-induced myocardial dysfunction and also an antioxidant [43]. We found S. cumini MSE to be enriched with polyphenols and had the potential to suppress HG-induced gelatinase-B activity in H9C2 cells which was comparatively better than that of gallic acid. The following major findings have emerged from this study: (i) S. cumini MSE phytoconstituents are cardioprotective against HG-induced changes in H9C2 cell morphology, (ii) S. cumini MSE polyphenols significantly suppress MMP-9 expression and activity in HG-induced H9C2 cells, and (iii) S. cumini MSE inhibits HG-induced nuclear localization of NF-κB and overexpression of TNF-α and IL-6, (iv) HPLC identified that S. cumini polyphenols show competitive inhibition with Zn$^{2+}$ ions for the metal-binding domain of gelatinase-B in molecular docking study. S. cumini polyphenols bind more efficiently than the currently available FDA-approved synthetic MMP inhibitor, doxycycline, indicating the potential use of S. cumini polyphenols as safe MMP inhibitors since S. cumini MSE alone did not cause any significant change in cellular viability and morphology.

The H9C2 cell line is an efficient in vitro model for studying cardiac stress as it emulates the responses similar to those observed in primary cardiomyocytes [44]. The concentration of high glucose used in this study reflects in vitro hyperglycemic diabetic stress [45].

Adult cardiac myocytes are terminally differentiated cell types which do not proliferate but execute various physiological functions. Under various stress conditions, cardiomyocytes enlarge and undergo hypertrophy, a compensatory cellular response of the heart to the imposed hemodynamic burden for an increased cardiac output [46]. The increase in cell size is a major hallmark of cardiac cell hypertrophy, and the agonists such as norepinephrine, isoproterenol, and glucose induce hypertrophy of cardiomyocytes, which cause reexpression of some fetal genes, for instance, atrial natriuretic factor (ANF), brain natriuretic peptide (BNP), and β-myosin heavy chain (β-MHC) [47].

We observed similar significant enlargement of cardiomyocytes upon exposure to HG, which was reversed by S. cumini MSE treatment suggesting potential cardioprotective effect of S. cumini against HG-induced stress. Enhanced activity of MMPs by high glucose may contribute to matrix reorganization, whereas marked reduction in MMP activity by MSE treatment showed its ability to reverse HG-induced changes in cardiomyocytes. In situ zymography, a relatively superior method that helps to map the activity within the cell, showed increased activity of MMPs that was prevented by S. cumini MSE. These data strongly support that MSE possesses strong MMP-inhibiting activity.

Gelatinase-A (MMP-2) is constitutively expressed in the heart while gelatinase-B is an inducible protease, and we conducted our further study with gelatinase-B due to its inducible response to various stimuli [48]. Indeed, elevated levels of gelatinase-B have been proposed as a serological cardiac stress marker as its expression increases markedly in diabetic cardiomyopathy [49]. Interestingly, we observed a mild induction of gelatinase-B expression on treatment with MSE extract alone. Since the MSE extract is a crude preparation, it may contain several other phytochemicals which may...
be responsible for this induction at baseline. Furthermore, the extract is protective under glucose-induced stress and behaves differently compared to baseline indicating its efficacy in disease conditions. Additionally, an increase in gelatinase-B expression may not be sufficient to create a functional effect, and we do not observe any effect of MSE extract on gelatinase-B activity at baseline.

To investigate the effect of S. cumini MSE on HG-induced gelatinase-B expression, we examined the activation and translocation of transcription factor NF-κB. In fact, gelatinase-B promoter is highly conserved and contains an NF-κB-binding site, and NF-κB is known to upregulate the production of MMP-9 when induced by various proinflammatory cytokines [50]. The present study shows that HG induced the localization of NF-κB from the cytoplasm to the nucleus indicating activation of gelatinase-B transcription. S. cumini MSE treatment regulated this alteration in nuclear localization of NF-κB leading to decreased expression of gelatinase-B in HG-stimulated cardiomyocytes. Additionally, MSE also downregulated the expression of inflammatory markers such as TNF-α and IL-6 which were known to be critical in cardiomyopathy [51].

Thus, our study demonstrates that S. cumini MSE can be used as a potential functional food to suppress the expression of proinflammatory cytokines and gelatinase-B in HG-induced stress in cardiomyocytes. Although a clear mechanism is not yet known, the presence of hydroxyl/carbonyl groups on the phenolic rings of a number of MMP inhibitors has been suggested to chelate active Zn$^{2+}$ ions and inhibit MMP activity [52].

S. cumini extracts prepared from different plant parts such as pulp, seed, leaves, and kernel have differential distribution of chemical constituents, especially the polyphenols, which are reported to possess a range of pharmacological potential. To know the status of polyphenols in MSE, a quantitative analysis was performed by HPLC, which indicated the presence of many polyphenols in MSE. The major polyphenols found in MSE (in 100 g of seed powder) were p-coumaric acid (71.9 ± 0.05 mg), gallic acid (53.0 ± 0.06 mg), protocatechuic acid (40.6 ± 0.10 mg), quercetin (29.6 ± 0.05 mg), sinapic acid (30.8 ± 0.14 mg), caffeic acid (15.8 ± 0.03 mg), kaempferol (10.2 ± 0.09 mg), ellagic acid (5.8 ± 0.09 mg), ferulic acid (2.71 ± 0.02 mg), and p-hydroxybenzoic acid (0.52 ± 0.04 mg) (Table S1).

The polyphenolic compounds that were identified and quantified in our study have been shown to exhibit cardioprotective potential as identified by various research groups using in vitro and models. p-Coumaric acid attenuated apoptosis in isoproterenol-induced myocardial infarction by inhibiting oxidative stress [53]. Gallic acid, a known cardioprotectant, has been found to suppress the expression of cardiac troponin-T, a cardiac arrest marker enzyme, lipid peroxidation products, and antioxidative enzymes [54].

Quercetin was reported to prevent endothelial dysfunction and decrease blood pressure, oxidative stress, and end-organ damage in hypertensive animals [55]. Derivatives of benzoic acid have been reported to activate Nrf2 signaling in the heart leading to overexpression of antioxidant enzymes, thereby decreasing oxidative stress and associated problems such as endothelial dysfunction and atherosclerosis [56].
Sinapic acid prevented ischemia/reperfusion, cardiac hypertension, and remodeling [57]. Caffeic acid derivatives exerted a protective effect during streptozotocin- and isoproterenol-induced cardiac stress [58]. Kaempferol has been reported to be cardioprotective by regulating the membrane-bound ATPases in streptozotocin-induced diabetic rats [59]. Ferulic acid is also found to suppress anticaner drug-induced cardiotoxicity [60]. Ellagic acid improved arrhythmic condition by upregulating endothelial nitric oxide synthase (eNOS) and alleviating oxidative stress [61]. These evidences strengthen and support our hypothesis that MSE, which is a mix of these polyphenolics, could be a potential cardioprotective agent in HG-induced stress.

The mechanism of MMP-mediated cardioprotection by these compounds is not yet known. To understand this further, the polyphenols identified in HPLC were used to study interaction with the MMP-9 active site. Our docking studies revealed good binding energies of HPLC-identified molecules with MMP-9. Such ligand-protein interaction was based upon the inhibitor/substrate binding site, suggesting that MMP-9 inhibition by S. cumini MSE was due to polyphenols present in MSE that act as competitive inhibitors with the substrate. The results of the docking study also explained that there was a direct interaction between gelatinase-B and the polyphenolic components of S. cumini MSE, which hindered its activity by targeting critical histidine residues of the metal-binding domain, thereby preventing the binding of Zn$^{2+}$ to the active site which in turn could inhibit MMP activity. The docking results suggested that S. cumini polyphenols especially quercetin, kaempferol, caffeic acid, and ferulic acid could be efficient MMP-9 inhibitors and thereby may be potential suppressors of HG-induced cardiac stress.

Structure-activity relationship (SAR) was established on the basis of results obtained in docking studies which revealed that the two structural elements, namely, chromone ring and hydroxyl groups in the aromatic ring of polyphenols, were the governing factors for the activity. Other MSE polyphenols also

![Figure 5: RT-PCR profiles of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in different experimental groups. Lane 1: control; Lane 2: glucose induced (GI); Lane 3: glucose induced+S. cumini methanol seed extract (GI+MSE) treated; Lane 4: MSE-treated alone (MSE); Lane 5: glucose induced+gallic acid treated (GI+GAL); Lane 6: gallic acid alone (GAL). (a) Semiquantitative PCR showed significant increase in expression for both the markers in the cells treated with high glucose (HG). S. cumini methanol seed extract (MSE) and gallic acid (GAL) treatment reduced it remarkably up to the control. (b) Results obtained by qRT-PCR (real-time PCR) were normalized against β-actin and represented by histogram (⁎ p ≤ 0.05).](image-url)
displayed satisfactory binding affinity with MMP-9 possibly due to the presence of hydroxyl groups.

It was also observed that polyphenols having the hydroxyl group attached directly to the benzene ring had more binding affinity (p-hydroxybenzoic and protocatechuic acid) as compared to those having hydroxyl groups in the side chains (sinapic acid). The following order of affinity has been observed in docking analysis: quercetin > kaempferol > ferulic acid > caffeic acid/p-coumaric acid > p-hydroxybenzoic acid/protocatechuic acid > sinapic acid > gallic acid. Our docking studies, therefore, correlated very well with SAR wherein maximum binding affinity of quercetin with MMP-9 was observed due to the presence of chromonering and five hydroxyl groups responsible for its excellent affinity with MMP-9. Henceforth, the docking and SAR data suggested that S. cumini MSE polyphenols may act as potent MMP-9 inhibitors.

The greatest hurdle in using herbal supplements as potential drugs has been that researchers try to identify a single bioactive molecule to modify certain pathological parameters, whereas practically the crude extracts containing many bioactive components show better pharmacodynamic synergistic potency [62]. The crude extracts could be more helpful as they are derived from natural plant parts which are usually biocompatible with the human system and thus would have low toxicity and higher bioavailability [63]. Our results also supported the concept of collaborative interaction of phytochemical-enriched S. cumini extract that could act in synergy for effective cardioprotection under high-glucose stress.

The polyphenol components of S. cumini MSE such as gallic acid alone are not used as dietary supplements as they inhibit the food intake as well as do not fulfill the criteria of effective oral dosing. Pharmacokinetic studies have shown that blood levels having $10^{-6}$ M concentration of gallic acid restrict the appropriate functioning of the transport system [64]. Therefore, proposing the potential use of such a plant extract as S. cumini as a MMP inhibitor would be advantageous in terms of its cost, availability, and safety.

In this regard, use of S. cumini as a nutritional supplement or functional food for diabetics prove to be a potent natural suppresser for gelatinase-B-mediated stress in HG-induced condition. Based on the data of the present study, a model can be proposed to understand the effect of S. cumini as a MMP inhibitor and a cardiac stress reliever via targeting the molecules at multiple levels. The study has significant relevance for the society as most of the identified MMP inhibitors possess severe side effects like musculoskeletal syndrome (MSS). Doxycycline is the only FDA-approved MMP inhibitor in the market currently that is only for periodontal diseases.

Our results show the strong interaction of phytochemicals with gelatinase-B that may act in synergy for effective cardioprotection under hyperglycemic stress. In this regard, the usage of S. cumini as functional food proved to be a potent natural suppresser for gelatinase-B-mediated HG-induced stress. A significant relationship between ECM integrity in HG-induced stress and the content of phenolic components of MSE supported this perception. Taken together, the present results suggest the potential of S. cumini MSE as an herbal-based therapy for the treatment of HG-induced cardiac stress. Due to the overwhelming potentials of S. cumini polyphenols, further in-depth analysis of the extract and validation on appropriate animal models are required to understand the precise mechanism for designing specific therapies against ECM remodeling in diabetic cardiomyopathy.

Myocardial remodeling could be categorized as either adaptive or pathological. Initial changes in the myocardium
may appear phenotypically similar in both cases, but the physiological effects of each are drastically different. Adaptive myocardial remodeling occurs due to high stress on the vascular walls or increased workload. It helps to counter the stress and restore normal ventricular function. Observations in the myocardium of high functioning athletes show changes in Left Ventricular (LV) geometry allowing improved compliance, enhanced filling through LV dilation, and better stroke volume [65]. On the other hand, in pathological remodeling, the LV chamber dilation leads to diminished compliance and significantly lower forward stroke volume [66]. MMP-2 has a crucial role in the progression of cardiac remodeling in response to pressure overload. An increase in MMP-2 activity can lead to fibrosis in LV hypertrophy, which may be due to direct proteolysis of cardiac ECM components, as well as by generating a profibrotic response, which further results in adaptive remodeling [67]. MMP-9 is a critical marker of LV remodeling; a higher MMP-9 level indicates more extensive adaptive LV remodeling [68]. It is also observed that in the patients having LV hypertrophy and with a history of hypertension, plasma levels of MMP-2 were significantly enhanced as compared to control subjects [67]. However, MMP-9 activates various chemokines, such as CXCL5, CXCL6, and CXCL8, releases cell surface receptors (e.g., tumor necrosis factor-α receptor), and eventually contributes to pathological remodeling. It has several other inflammatory mediators such as activator protein-1, specificity protein-1, and NF-κB sites that make it a possible target for myocardial remodeling in atherosclerosis and heart failure [69].

5. Conclusion

In conclusion, the present study on the one hand highlights the role of MMPs, especially gelatinase-B, in HG-induced cardiomyopathy in rat heart-derived H9C2 cardiomyoblast cells, and on the other hand, it elaborates the role of S. cumini MSE in suppressing HG-stimulated gelatinase-B expression and activity in cardiomyocytes. Further, strong binding energy of interaction of S. cumini polyphenols and gelatinase-B protein suggests close interaction of the polyphenols with gelatinase-B which could be responsible for its inhibition. Taken together, being a potent source of polyphenols with MMP inhibition potential, S. cumini may be useful as a functional food and dietary supplement in HG-induced
and gelatinase-B-mediated cardiac stress and cardiomyopathy. This study will certainly enhance the scientific opportunities in deriving the novel inhibitors from functional foods in developing countries.

Data Availability
Data will be available on request.

Disclosure
Shrey Kohli is presently in the Institute for Clinical Chemistry and Pathobiology, Otto Von Guericke University (Medical Faculty), Universitätsklinikum, Haus 39 Leipziger Str 44, 39120 Magdeburg, Germany.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
Neha Atale and Chandra Bhushan Mishra contributed equally to this work.

Acknowledgments
We acknowledge Jaypee Institute of Information Technology, Deemed to be University, for providing infrastructural support. This research work was funded by the National Research Foundation (NRF) of Korea, supported by the Korean government (MSIP) (Grant Nos: 2019R1F1A1057386 and 2019H1D3A2A02102142).

Supplementary Materials

Supplementary 1. Fig. S1: schematics of the methodology adopted to study the protective effect of S. cumini methanol seed extract (MSE) on high-glucose- (HG-) induced cardiac stress.

Supplementary 2. Fig. S2: HPLC chromatogram: (A) gallic acid and p-coumaric acid, (B) quercetin and ellagic acid, (C) kaempferol and ferulic acid, (D) protocatechuic acid and sinapic acid, and (E) caffeic acid and p-hydroxybenzoic acid.

Supplementary 3. Table S1: HPLC analysis of methanol seed extract of S. cumini.

References

[1] S. Sneha and D. Madhusweta, "Nutritive, therapeutic and processing aspects of Jamun, Syzygium cumini (L.) sklees- an overview," Indian Journal of Natural Product Research, vol. 5, pp. 295–307, 2014.

[2] A. G. V. Costa, D. F. Garcia-Diaz, P. Jimenez, and P. I. Silva, "Bioactive compounds and health benefits of exotic tropical red-black berries," Journal of Functional Foods, vol. 5, no. 2, pp. 539–549, 2013.

[3] S. G. Jaiswal, M. Patel, and S. N. Naik, "Physico-chemical properties of Syzygium cuminii (L.) Skeels jam and comparative antioxidant study with other fruit jams," Indian Journal of Natural Products and Resources, vol. 6, pp. 9–15, 2015.

[4] B. S. Shrikant, S. J. T. Nayan, M. P. Meghatai, and M. H. Parag, "Jamun (Syzygium cumini (L.)): a review of its food and medicinal uses," Food and Nutrition Sciences, vol. 3, pp. 1100–1117, 2012.

[5] Y. C. Cheng, J. M. Sheen, W. L. Hu, and Y. C. Hung, "Polyphenols and oxidative stress in atherosclerosis-related ischemic heart disease and stroke," Oxidative Stress & Cellular Longevity, vol. 17, pp. 1–16, 2017.

[6] M. Ayyar and P. Subash-Babu, "Syzygium cumini (L.) sklees: a review of its phytochemical constituents and traditional uses," Asian Pacific Journal of Tropical Biomedicine, vol. 2, no. 3, pp. 240–246, 2012.

[7] A. C. Dametto, D. Agustoni, T. F. Moreira et al., "Chemical composition and _in vitro_ chemoprevention assessment of _Eugenia jambolana_ Lam. (Myrtaceae) fruits and leaves," Journal of Functional Foods, vol. 36, pp. 490–502, 2017.

[8] A. Rawshani, A. Rawshani, S. Franzen et al., "Mortality and cardiovascular disease in type 1 and type 2 diabetes," New England Journal of Medicine, vol. 376, no. 15, pp. 1407–1418, 2017.

[9] T. R. Einarsen, A. Acs, C. Ludwig, and U. H. Panton, "Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017," Cardiovascular Diabetology, vol. 17, no. 1, pp. 83–102, 2018.

[10] M. Valko, D. Leibfritz, J. Moncol, M. T. D. Cronin, M. Mazur, and J. Telser, "Free radicals and antioxidants in normal physiological functions and human disease," International Journal of Biochemistry and Cell Biology, vol. 39, no. 1, pp. 44–84, 2007.

[11] M. K. Lindsey and T. K. Borg, "Understanding the role of the extracellular matrix in cardiovascular development and disease: where do we go from here?," Journal of Molecular and Cellular Cardiology, vol. 48, no. 3, pp. 431–432, 2010.

[12] M. Bellafiore, G. Battaglia, A. Bianco, F. Farina, A. Palma, and A. Paoli, "The involvement of MMP-2 and MMP-9 in heart exercise-related angiogenesis," Journal of Translational Medicine, vol. 11, no. 1, pp. 283–290, 2013.

[13] S. A. Peeters, L. Engelen, J. Buijs et al., "Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study," Cardiovascular Diabetology, vol. 16, no. 1, pp. 55–67, 2017.

[14] K. Brew and H. Nagase, "The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity," Biochimica et Biophysica Acta, vol. 1803, no. 1, pp. 55–71, 2010.

[15] S. Naphade, A. Embusch, K. L. Madushani, K. L. Ring, and L. M. Ellerby, "Altered expression of matrix metalloproteinases and their endogenous inhibitors in a human isogenic stem cell model of Huntington’s disease,” Frontiers in Neuroscience, vol. 11, 2018.

[16] C.-W. Lee, C.-C. Lin, W.-N. Lin et al., "TNF-α induces MMP-9 expression via activation of Src/EGFR, PDGFR/Pi3K/Akt cascade and promotion of NF-κB/p300 binding in human tracheal smooth muscle cells," American Journal of Physiology Lung Cell and Molecular Physiology, vol. 292, no. 3, pp. L799–L812, 2007.

[17] A. Yabluchanskiy, Y. Ma, A. P. Iyer, M. E. Hall, and M. L. Lindsey, "Matrix metalloproteinase-9: many shades of
function in cardiovascular disease,” *Physiology*, vol. 28, no. 6, pp. 391–403, 2013.

[18] B. Fingleton, “Matrix metalloproteinases as valid clinical target,” *Current Pharmaceutical Design*, vol. 13, no. 3, pp. 333–346, 2007.

[19] Y. Y. Li, C. F. McTiernan, and A. M. Feldman, “Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling,” *Cardiovascular Research*, vol. 46, no. 2, pp. 214–224, 2000.

[20] P. K. Mishra, V. Chavali, N. Metreveli, and S. C. Tyagi, “Ablation of MMP9 induces survival and differentiation of cardiac stem cells into cardiomyocytes in the heart of diabetics: a role of extracellular matrix,” *Canadian Journal of Physiology and Pharmacology*, vol. 90, no. 3, pp. 353–360, 2012.

[21] V. Mohan, D. Talmi-Frank, V. Arkadash, N. Papo, and I. Sagi, “Matrix metalloproteinase protein inhibitors: highlighting a new beginning for metalloproteinases in medicine,” *Dovepress*, vol. 2016, pp. 31–47, 2016.

[22] J. Hever and R. J. Cronise, “Plant-based nutrition for health-care professionals: implementing diet as a primary modality in the prevention and treatment of chronic disease,” *Journal of Geriatric Cardiology*, vol. 14, no. 5, pp. 355–368, 2017.

[23] L. Crasci, M. R. Lauro, G. Puglisi, and A. Panico, “Natural antioxidant polyphenols on inflammation management: anti-glycation activity vs metalloproteinases inhibition,” *Critical Reviews in Food Science & Nutrition*, vol. 58, pp. 893–904, 2017.

[24] N. Wang, Z.-Y. Wang, S.-L. Mo et al., “Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer,” *Breast Cancer Research Treatment*, vol. 134, no. 3, pp. 943–955, 2012.

[25] K. Amutha and S. Aishwarya, “Evaluation of antibacterial and antidiabetic activity and phytochemical analysis of *Syzygium cumini* seeds. Seed,” *Research Journal of Pharmacology and Pharmacodynamics*, vol. 2, no. 5, pp. 348–350, 2010.

[26] N. Atale, S. Malhotra, G. Nirmala, R. T. Narendhirakannan, S. Mohanty, and V. Rani, “Synthesis and characterization of *Syzygium* cumini nanoparticles for its protective potential in high glucose induced cardiac stress: a green approach,” *Applied Biochemistry and Biotechnology*, vol. 181, no. 3, pp. 1140–1154, 2017.

[27] P. Sreejit, S. Kumar, and R. S. Verma, “An improved protocol for primary culture of cardiomyocyte from neonatal mice,” *In vitro Cell Developmental Biology Animal*, vol. 44, no. 3-4, pp. 45–50, 2008.

[28] N. Atale, M. Chakraborty, S. Mohanty et al., “Cardioprotective role of *Syzygium* cumini against glucose-induced oxidative stress in *H9C2* cardiac myocytes,” *Cardiovascular Toxicology*, vol. 13, no. 3, pp. 278–289, 2013.

[29] N. Atale, K. Gupta, and V. Rani, “Protective effect of *Syzygium* cumini against pesticide-induced cardiotoxicity,” *Environmental Science Pollution Research International*, vol. 21, no. 13, pp. 7956–7972, 2014.

[30] C. B. Mishra, S. Kumari, A. Angeli, S. Bua, M. Tiwari, and C. T. Supuran, “Discovery of benzanesulfonamide derivatives as carbonic anhydrase inhibitors with effective anticonvulsant action: design, synthesis, and pharmacological evaluation,” *Journal of Medicinal Chemistry*, vol. 61, no. 7, pp. 3151–3165, 2018.

[31] C. B. Mishra, S. Kumari, A. Angeli et al., “Discovery of potent anti-convulsant carbonic anhydrase inhibitors: design, synthesis, in vitro and in vivo appraisal,” *European Journal of Medicinal Chemistry*, vol. 156, pp. 430–443, 2018.

[32] C. B. Mishra, S. Kumari, A. Angeli et al., “Discovery of benzanesulfonamide with potent human carbonic anhydrase inhibitory and effective anticonvulsant action: design, synthesis and pharmacological assessment,” *Journal of Medicinal Chemistry*, vol. 60, no. 6, pp. 2456–2469, 2017.

[33] O. Trott and A. J. Olson, “AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading,” *Journal of Computational Chemistry*, vol. 31, no. 2, pp. 455–461, 2009.

[34] N. Kumar, C. B. Mishra, A. Prakash, N. Kumar, R. Mongre, and P. M. Luthra, “8-(Furan-2-yl)-3-phenethylthiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidine-2(3H)-thione as novel, selective and potent adenosine A2A receptor antagonist,” *Neuroscience Letters*, vol. 558, pp. 203–207, 2014.

[35] C. B. Mishra, D. Sharma, A. Prakash, N. Kumar, N. Kumari, and P. M. Luthra, “Design and synthesis of (4E)-4-(4-substitutedbenzylidenamino)-3-substituted-2,3-dihydro-2-thioxothiazole-5-carbonitrile as novel A2A receptor antagonists,” *Bioorganic & Medicinal Chemistry*, vol. 21, no. 19, pp. 6077–6083, 2013.

[36] S. K. Barodia, C. B. Mishra, A. Prakash, J. B. S. Kumar, N. Kumari, and P. M. Luthra, “Novel 8-(furan-2-yl)-3-benzylthiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidine-2(3H)-thione as selective adenosine A2A receptor antagonist,” *Neuroscience Letters*, vol. 488, no. 1, pp. 1–5, 2011.

[37] C. B. Mishra, S. K. Barodia, A. Prakash, and P. M. Luthra, “Novel 8-(furan-2-yl)-3-substituted thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidine-2(3H)-thione derivatives as potential adenosine A2A receptor antagonists,” *Bioorganic & Medicinal Chemistry*, vol. 18, no. 7, pp. 2491–2500, 2010.

[38] C. B. Mishra, P. Pandey, R. D. Sharma et al., “Identifying the natural phenol catechin as a multigated agent against SARS-CoV-2 for the plausible therapy of COVID-19: an integrated computational approach,” *Briefings in Bioinformatics*, vol. bbaa378, 2020.

[39] P. M. Luthra, A. Prakash, S. K. Barodia, R. Kumari, C. B. Mishra, and J. B. S. Kumar, “In silico study of naphtha[1, 2-d] thiazol-2-amine with adenosine A2A receptor and its role in antagonism of haloperidol- induced motor impairments in mice,” *Neuroscience Letters*, vol. 463, no. 3, pp. 215–218, 2009.

[40] K. T. Khaw, N. Wareham, S. Bingham, R. Luben, A. Welch, and N. Day, “Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk,” *Annals of Internal Medicine*, vol. 141, no. 6, pp. 413–420, 2004.

[41] R. E. Vandenbroucke and C. Libert, “Is there new hope for therapeutic matrix metalloproteinase inhibition?”, *Nature Reviews Drug Discovery*, vol. 13, no. 12, pp. 904–927, 2014.

[42] Y. Wang, L. Zhao, C. Wang et al., “Protective effect of quercetin and chlorogenic acid, two polyphenols widely present in edible plant varieties, on visible light-induced retinal degeneration in vivo,” *Journal of Functional Foods*, vol. 33, pp. 103–111, 2017.

[43] S. P. Snehal and K. G. Ramesh, “Cardioprotective effects of gallic acid in diabetes-induced myocardial dysfunction in rats,” *Pharmacognosy Research*, vol. 3, pp. 239–245, 2011.

[44] S. J. Watkins, G. M. Borthwick, and H. M. Arthur, “The H9C2 cell line and primary neonatal cardiomyocyte cells show similar hypertrophic responses in vitro,” *In vitro Cell Developmental Biology Animal*, vol. 47, no. 2, pp. 125–131, 2011.
[45] F. Deng, S. Wang, L. Zhang et al., "Propofol through upregulating caveolin-3 attenuates post-hypoxic mitochondrial damage and cell death in H9C2 cardiomyocytes during hyperglycemia," *Cellular Physiology and Biochemistry*, vol. 44, no. 1, pp. 279–292, 2018.

[46] S. Kohli, S. Ahuja, and V. Rani, "Transcription factors in heart: promising therapeutic targets in cardiac hypertrophy," *Current Cardiology Reviews*, vol. 7, no. 4, pp. 262–271, 2011.

[47] S. Ahuja, S. Kohli, S. Krishnan, D. Dogra, D. Sharma, and V. Rani, "Curcumin: a potential therapeutic polypehloen, prevents noradrenaline-induced hyper trophy in rat cardiac myocytes," *Journal of Pharmacy and Pharmacology*, vol. 63, no. 12, pp. 1604–1612, 2011.

[48] J. M. Parente and M. M. Castro, "Matrix metalloproteinase in the cardiovascular remodeling of hypertension: current insights and therapeutic potential," *Metalloproteinases In Medicine*, vol. Volume 5, pp. 1–11, 2018.

[49] G. Li, W. Xing, M. Zhang et al., "Antibiotic cardioprotection of berberine via downregulating myocardial IGF-1 receptor-regulated MMP-2/MMP-9 expression in diabetic rats," *American Journal of Physiology Heart & Circulatory Physiology*, vol. 315, no. 4, pp. H802–H813, 2018.

[50] S. O. Sullivan, C. Medina, M. Ledwidge, M. W. Radomski, and J. F. Gilmer, "Nitric oxide-matrix metalloproteinase-9 interactions: biological and pharmacological significance: NO and MMP-9 interactions," *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*, vol. 1843, no. 3, pp. 603–617, 2014.

[51] N. A. Turner and K. E. Porter, "Regulation of myocardial matrix metalloproteinase expression and activity by cardiac fibroblasts," *IUBMB Life*, no. 4, pp. 143–150, 2012.

[52] F. Mannello, "Natural bio-drugs as matrix metalloproteinase inhibitors: new perspectives on the horizon?", *Recent Patents on Anti Cancer Drug Discovery*, vol. 1, no. 1, pp. 91–103, 2006.

[53] P. S. M. Prince and A. J. Roy, "p-Coumaric acid attenuates apoptosis in isoproterenol-induced myocardial infarcted rats by inhibiting oxidative stress," *International Journal of Cardiology*, vol. 168, no. 4, pp. 3259–3266, 2013.

[54] D. H. Priscilla and P. S. Prince, "Cardioprotective effect of gallic acid on cardiac troponin-T, cardiac marker enzymes, lipid peroxidation products and antioxidants in experimentally induced myocardial infarction in Wistar rats," *Chemico-Biological Interaction*, vol. 179, no. 2–3, pp. 118–124, 2009.

[55] R. L. Castillo, E. A. Herrera, A. G. Candia et al., "Quercetin prevents diastolic dysfunction induced by a high-cholesterol diet: role of oxidative stress and bioenergetics in hyperglycemic rats," *Oxidative Medicine & Cellular Longevity*, vol. 2018, pp. 1–14, 2018.

[56] B. H. Juurlink, H. J. Azouz, B. M. A'Tinawi, and P. Ganguley, "Hydroxybenzoic acid isomers and the cardiovascular system," *Nutrition*, vol. 13, no. 1, pp. 63–72, 2014.

[57] T. Silambarasan, J. Manivannan, M. KrishnaPriya, N. Suganya, S. Chatterje, and B. Raja, "Sinapic acid prevents hypertension and cardiovascular remodeling in pharmacological model of nitric oxide inhibited rats," *PLoS One*, vol. 9, no. 12, article e115682, 2014.

[58] Y.-J. Ho, A.-S. Lee, W.-P. Chen et al., "Caffeic acid phenethyl amide ameliorates ischemia/reperfusion injury and cardiac dysfunction in streptozotocin-induced diabetic rats," *Cardiovascular Diabetology*, vol. 13, no. 1, pp. 98–110, 2014.

[59] M. Zhou, H. Ren, J. Han, W. Wang, Q. Zheng, and D. Wang, "Protective effects of kaempferol against myocardial ische-